Prognostic value of elevated high-sensitivity cardiac troponin T levels in patients with acute ischemic stroke treated with endovascular thrombectomy. (June 2019)

• Record Type: Journal Article
• Authors: Cao, Yue-Zhou; Zhao, Lin-Bo; Liu, Sheng; Liu, Qiang-Hui; Jiang, Lei; Zhou, Chun-Gao; Jia, Zhen-Yu; Zhou, Wei-Zhong; Xia, Jin-Guo; Wu, Wen-Tao; Zu, Qing-Quan; Lu, Shan-Shan; Xu, Xiao-Quan; Shi, Hai-Bin
• Is Part Of: Journal of clinical neuroscience. Volume 64(2019)
• Page Start: 145
• Page End: 149
• Publication Date: 2019-06
• Subjects: High-sensitivity cardiac troponin T -- Acute ischemic stroke -- Endovascular thrombectomy -- Prognostic; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2019.03.030
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: About 40% of the patients showed elevated hs-cTnT levels before ET. Hs-cTnT elevation is an independent predictor of 3-month mortality after ET. Admission NIHSS, CHD and CHF are independently associated with hs-cTnT elevation. Abstract: Our objective was to assess the impact of hs-cTnT elevation on functional outcome and mortality in AIS patients with large vessel occlusion (LVO) in the anterior circulation 3 months after ET and explore factors affecting hs-cTnT elevation. A total of 143 consecutive AIS patients with large vessel occlusion (LVO) in the anterior circulation following ET in a single stroke center were enrolled between January 2015 and November 2017. Hs-cTnT was quantitated on admission. Demographic characteristics, clinical data, functional outcome and all-cause mortality were compared between patients with elevated hs-cTnT levels (>14 ng/L) and those with normal hs-cTnT levels (≤14 ng/L). 58/143(40.6%) patients showed elevated hs-cTnT levels before ET. Factors independently associated with hs-cTnT elevation were admission NIHSS score (OR = 1.08, 95% CI 1.01–1.16, p = 0.032), coronary heart disease (OR = 4.89, 95% CI 1.82–13.11, p = 0.002) and congestive heart failure (OR = 4.10, 95% CI 1.07–15.68, p = 0.039). In the univariate analysis, patients with elevated hs-cTnT levels were at significantly higher risk of 3-month poor outcome (p = 0.029) and mortality (p < 0.001) than those with normal hs-cTnT levels. After multivariable analysis, hs-cTnT elevation remained an independent predictor of 3-month mortality (OR = 4.49, 95% CI 1.68–11.98, p = 0.003). In this cohort of AIS patients with LVO in the anterior circulation undergoing ET, hs-cTnT elevation is an independent predictor of 3-month mortality. Admission NIHSS score, coronary heart disease and congestive heart failure are independently associated with elevated hs-cTnT levels.